Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Insomnia in Alcohol Dependence
NCT03897062Phase 2Terminated
- Sponsor
- Florey Institute of Neuroscience and Mental Health
- Start
- Aug 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suvorexant in Insomnia and alcohol use disorder (AUD) (2 arms), sponsored by Florey Institute of Neuroscience and Mental Health. Primary endpoint: Sleep measure. Started Aug 2019; status: terminated.
02
Drugs
suvorexant
03
Conditions
Insomniaalcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03897062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897062.